{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:33:27Z","timestamp":1794476007276,"version":"4.9.1"},"reference-count":32,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2016,12,27]],"date-time":"2016-12-27T00:00:00Z","timestamp":1482796800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Sanofi and Regeneron Pharmaceuticals, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Cardiology"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Lowering low\u2010density lipoprotein cholesterol with statins reduces risk of cardiovascular events. We examined patterns and predictors of filled prescriptions for lipid\u2010lowering therapy (LLT) in subgroups of patients with atherosclerotic cardiovascular disease (<jats:styled-content style=\"fixed-case\">ASCVD<\/jats:styled-content>) and\/or diabetes mellitus (<jats:styled-content style=\"fixed-case\">DM<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Hypothesis<\/jats:title><jats:p>Statin treatment remains underutilized across subgroups of high CV risk patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients in the Optum Research Database with these criteria were included: age \u226520\u2009years, 2 years continuous enrollment, and <jats:styled-content style=\"fixed-case\">ASCVD<\/jats:styled-content> and\/or <jats:styled-content style=\"fixed-case\">DM<\/jats:styled-content>. Patients were hierarchically classified by the presence of recent acute coronary syndrome, other coronary heart disease, ischemic stroke, peripheral arterial disease (<jats:styled-content style=\"fixed-case\">PAD<\/jats:styled-content>), or only <jats:styled-content style=\"fixed-case\">DM<\/jats:styled-content>. Predictors of filled LLT regimens were examined using multinomial logistic regression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 1\u2009055\u2009932 individuals met all inclusion criteria. Evidence by point\u2010in\u2010time analysis of filled (not only written) statin prescriptions was 45% for the overall cohort. By subgroups, this was 62%, 52%, 43%, 36%, and 40% for recent acute coronary syndrome, other coronary heart disease, ischemic stroke, <jats:styled-content style=\"fixed-case\">PAD<\/jats:styled-content>, and only <jats:styled-content style=\"fixed-case\">DM<\/jats:styled-content>, respectively. Predictors of higher rates of any statin regimen included age 50 to 69 years, male sex, absence of comorbidities, and filled prescriptions of other standard\u2010of\u2010care therapies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In 2014, only 49% of patients with <jats:styled-content style=\"fixed-case\">ASCVD<\/jats:styled-content> and 40% with only <jats:styled-content style=\"fixed-case\">DM<\/jats:styled-content> had evidence for a filled statin prescription. Those with indications of ischemic stroke, <jats:styled-content style=\"fixed-case\">PAD<\/jats:styled-content>, and <jats:styled-content style=\"fixed-case\">DM<\/jats:styled-content> were less likely to receive statins than those with coronary conditions. Other characteristics such as advanced age, female sex, and noncardiac conditions predicted less statin utilization, thereby representing good targets for quality improvement.<\/jats:p><\/jats:sec>","DOI":"10.1002\/clc.22641","type":"journal-article","created":{"date-parts":[[2016,12,27]],"date-time":"2016-12-27T12:43:02Z","timestamp":1482842582000},"page":"155-162","source":"Crossref","is-referenced-by-count":41,"title":["Patterns and predictors of lipid\u2010lowering therapy in patients with atherosclerotic cardiovascular disease and\/or diabetes mellitus in 2014: Insights from a large <scp>US<\/scp> managed\u2010care population"],"prefix":"10.1002","volume":"40","author":[{"given":"Dylan L.","family":"Steen","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Health and Disease University of Cincinnati Medical Center  Cincinnati Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irfan","family":"Khan","sequence":"additional","affiliation":[{"name":"Global Health Economics and Outcomes Research, Sanofi, Bridgewater  New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Becker","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research, Optum  Eden Prairie Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoAnne M.","family":"Foody","sequence":"additional","affiliation":[{"name":"Formerly of: Cardiovascular Division Brigham and Women's Hospital  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Gorcyca","sequence":"additional","affiliation":[{"name":"Global Health Economics and Outcomes Research, Sanofi, Bridgewater  New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Sanchez","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research, Regeneron Pharmaceuticals Inc., Tarrytown  New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Giugliano","sequence":"additional","affiliation":[{"name":"Cardiovascular Division Brigham and Women's Hospital  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,12,27]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60367-5"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.624890"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.09.088"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2016.06.011"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1370\/afm.1641"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.08.041"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2258"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.003954"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.109.573618"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.2.180"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2015.02.003"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1161\/circ.131.suppl_2.o29"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.22577"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.113.000112"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2013.12.040"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.003589"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.04.102"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2010.08.041"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1107913"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-012-0291-7"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2006.08.007"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.14850"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.11.002"},{"key":"e_1_2_7_26_1","unstructured":"FDA approves first version of cholesterol\u2010lowering drug lipitor [press release]. Silver Spring MD: US Food and Drug Administration; March 10 2014.http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm281817.htm. Accessed September 2016."},{"key":"e_1_2_7_27_1","unstructured":"US Food and Drug Administration. First generic drug approvals.http:\/\/www.fda.gov\/drugs\/developmentapprovalprocess\/howdrugsaredevelopedandapproved\/drugandbiologicapprovalreports\/andagenericdrugapprovals\/default.htm. Accessed September 2016."},{"key":"e_1_2_7_28_1","first-page":"430","article-title":"Impact of the new ACC\/AHA guidelines on the treatment of high blood cholesterol in a managed care setting [published correction appears in Am Health Drug Benefits. 2014;7:487\u2013488]","volume":"7","author":"Tran JN","year":"2014","journal-title":"Am Health Drug Benefits"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315665"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.22503"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.22343"},{"key":"e_1_2_7_32_1","first-page":"2105","article-title":"A comparison of ezetimibe\/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes","volume":"130","author":"Cannon CP","year":"2014","journal-title":"Circulation"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.03.519"}],"container-title":["Clinical Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fclc.22641","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fclc.22641","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clc.22641","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T10:54:03Z","timestamp":1696589643000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clc.22641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,27]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1002\/clc.22641"],"URL":"https:\/\/doi.org\/10.1002\/clc.22641","archive":["Portico"],"relation":{},"ISSN":["0160-9289","1932-8737"],"issn-type":[{"value":"0160-9289","type":"print"},{"value":"1932-8737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,27]]}}}